Amish Chinoy,Raja Padidela
Refractory Rickets
Phosphate homeostasis,Vitamin D-dependent rickets,X-linked hypophosphatemic rickets,FGF23,PTH
Nutritional rickets, caused by vitamin D and/or calcium deficiency is by far the most common cause of rickets. In resource-limited settings, it is therefore not uncommon to treat rickets with vitamin D and calcium. If rickets fails to heal and/or if there is a family history of rickets, then refractory rickets should be considered as a differential diagnosis. Chronic low serum phosphate is the pathological hallmark of all forms of rickets as its low concentration in extracellular space leads to the failure of apoptosis of hypertrophic chondrocytes leading to defective mineralisation of the growth plate. Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) control serum phosphate concentration by facilitating the excretion of phosphate in the urine through their action on the proximal renal tubules. An increase in PTH, as seen in nutritional rickets and genetic disorders of vitamin D-dependent rickets (VDDRs), leads to chronic low serum phosphate, causing rickets. Genetic conditions leading to an increase in FGF23 concentration cause chronic low serum phosphate concentration and rickets. Genetic conditions and syndromes associated with proximal renal tubulopathies can also lead to chronic low serum phosphate concentration by excess phosphate leak in urine, causing rickets. In this review, authors discuss an approach to the differential diagnosis and management of refractory rickets.
Refractory Rickets

Nutritional rickets, caused by vitamin D and/or calcium deficiency is by far the most common cause of rickets. In resource-limited settings, it is therefore not uncommon to treat rickets with vitamin D and calcium. If rickets fails to heal and/or if there is a family history of rickets, then refractory rickets should be considered as a differential diagnosis. Chronic low serum phosphate is the pathological hallmark of all forms of rickets as its low concentration in extracellular space leads to the failure of apoptosis of hypertrophic chondrocytes leading to defective mineralisation of the growth plate. Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) control serum phosphate concentration by facilitating the excretion of phosphate in the urine through their action on the proximal renal tubules. An increase in PTH, as seen in nutritional rickets and genetic disorders of vitamin D-dependent rickets (VDDRs), leads to chronic low serum phosphate, causing rickets. Genetic conditions leading to an increase in FGF23 concentration cause chronic low serum phosphate concentration and rickets. Genetic conditions and syndromes associated with proximal renal tubulopathies can also lead to chronic low serum phosphate concentration by excess phosphate leak in urine, causing rickets. In this review, authors discuss an approach to the differential diagnosis and management of refractory rickets.

Rickets describes a deficiency in the mineralisation of bone at the growth plate. The common pathway to all forms of rickets is a low serum phosphate, either directly due to renal phosphate wasting (hypophosphatemic rickets) or secondary to hyperparathyroidism (in cases of calcium or vitamin D-related rickets). The low serum phosphate impairs the apoptosis of terminally differentiated chondrocytes in the growth plate, which results in the presenting features of rickets [1]. By far the commonest cause of rickets is nutritional rickets, due to dietary deficiency in calcium and/or vitamin D intake. Therefore, it would be common practice, particularly in resource-deprived settings, to treat cases of rickets presenting clinically empirically with oral calcium and vitamin D supplementation. However, if despite adequate compliance to these regimes, rickets persists, then ‘refractory’ causes of rickets must be considered. These can be subdivided into those that affect phosphate metabolism (hypophosphatemic rickets) and those that affect vitamin D metabolism (vitamin D-dependent rickets). Indeed, if biochemical testing for rickets has been undertaken prior to treatment for nutritional rickets, then clues to the small proportion of cases of refractory rickets can be established (Table 1). This review article describes the current and up-to-date knowledge of these refractory forms of rickets.

The skeletal system stores 90% of body phosphate; outside the skeleton almost all of the phosphate is intracellular. Phosphate is therefore predominantly an intracellular ion and most of its physiological function and structural role is within the cells [2]. The bones store most of the body’s phosphate and its extracellular function is predominantly in bones where (a) it forms part of hydroxyapatite crystal (the mineral component of the bones) and (b) facilitates the mineralisation of the growth plate by causing apoptosis of the hypertrophic chondrocytes [1]. Most of the hormones required for calcium and phosphate homeostasis are common such as calcitriol [1,25,(OH)2D], parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23). Phosphate absorption from the gut is either passive, across the concentration gradient, through the paracellular route while active absorption is transcellular and occurs through sodium-phosphate cotransporter 2b (NPT2b), the expression of which is controlled by 1,25(OH)2D. Since most diets are rich in phosphate, passive absorption sufficiently absorbs the required phosphate and active absorption is seldom required. Retrieval of phosphate from the glomerular filtrate is mediated through sodium-phosphate cotransporter 2a and 2c (NPT2a and NPT2c) located in the luminal surface of the cells of proximal renal tubules. PTH and FGF23 facilitate the excretion of phosphate in the urine by reducing the expression of NPT2a and NPT2c.

Low serum phosphate concentration leads to failure of its extracellular function of mineralisation of osteoid tissue and apoptosis of hypertrophic chondrocytes causing osteomalacia and rickets respectively. Dietary phosphate deficiency causing rickets is unheard of as most diets are rich in phosphate; all forms of phosphopenic rickets are therefore secondary to excess loss of phosphate in urine either mediated through excess FGF23 or proximal renal tubular disorders (inherited genetic disorders or drug-induced). High FGF23-related hypophosphatemic rickets is caused by genetic disorders which are mentioned in Table 2. Non-FGF23–mediated renal tubular dysfunction and associated hypophosphatemia are also mentioned in Table 2.

In comparison to nutritional rickets, phosphopenic rickets is rare and therefore, in the absence of family history, it is not uncommon for most of the cases to be initially diagnosed and managed as nutritional rickets. X-linked hypophosphatemic (XLH) rickets is the most common form of phosphopenic rickets with an incidence of approximately 1 in 20–25,000 individuals [3]. It is an X-linked dominant disorder caused by a pathogenic variant in the PHLEX gene which increases the concentration of circulating intact FGF23. XLH becomes clinically apparent in late infancy or early childhood when rickets develops in weight-bearing joints. Most children present with rickets, waddling gait and bowed legs which are not responsive to standard treatment for nutritional rickets. Muscle pain and weakness are less prominent than nutritional rickets. Short stature is universal in children unless treatment is commenced in early infancy in those who have a family history of XLH. Some children present in mid/late childhood with genu valgum and, in isolation or combinations of symptoms of, short stature, multiple dental abscesses and craniosynostosis. A family history of XLH helps in early diagnosis and treatment. Infants with XLH can have normal serum phosphate for 6 mo or more; therefore, biochemical screening in early infancy is generally not reliable in confirming the diagnosis and hence genetic testing should be undertaken to confirm the diagnosis. Clinical features of all the others forms of hypophosphatemic rickets are summarised in Table 2.

The biochemical hallmark of hypophosphatemic rickets is low serum phosphate, elevated alkaline phosphatase, low TmP/GFR and normal or marginally elevated PTH. Serum phosphate and alkaline phosphatase concentrations vary with age with higher concentrations in infants and children; adult values are reached after the completion of puberty. Hence age-appropriate reference ranges should be used [4]. Serum alkaline phosphatase serves as an important biomarker of the activity of rickets and for monitoring treatment [5]. All forms of phosphopenic rickets are caused by renal loss of phosphate and in children measurement of TmP/GFR using the equation: TmP/GFR = serum phosphate – [(urine phosphate × serum creatinine)/urine creatinine] allows assessment of renal capacity to reabsorb phosphate [6]. TmP/GFR essentially represents the theoretical lower limit of serum phosphate below which all filtered phosphate would be reabsorbed. Age-adjusted normal ranges are available for TmP/GFR and as a general rule at any age, it is similar to the normal serum phosphate ranges for the age [7]. Genetic testing to confirm the pathogenic variants casing hypophosphatemic rickets is the gold standard in confirming the diagnosis. Gene panel is more cost-effective compared to single gene testing and should be undertaken if finance and facilities are available. Genetic testing allows confirmation of diagnosis, firm assurance on management protocol to follow and genetic counseling for prognosis and future pregnancies. Radiographs of children with high FGF23 hypophosphatemia are distinct from nutritional rickets (Fig. 1) with thicker cortices, coarse trabeculations, rickets affecting weight-bearing lower limb bones and either medial or lateral condyles more significantly affected than the other, medial in genu varum and lateral in genu valgum.

Management of FGF23-related hypophosphatemia (Table 2) is with oral phosphate supplements and active vitamin D analogues, alfacalcidol or calcitriol. Non-FGF23-related hypophosphatemia (Table 2) is managed with oral phosphate alone; active vitamin D analogues are contraindicated in these conditions. Additional solutes (potassium, bicarbonate and/or calcium) may be required in non-FGF23 related hypophosphatemia if there is proximal renal tubular acidosis with aminoaciduria. Recent consensus guidance suggests using elemental phosphorus of 20–60 mg/kg body weight daily (0.7–2.0 mmol/kg daily) [8]. Since phosphorus is rapidly absorbed and excreted in the urine, 4–5 doses are required; doses >80 mg/kg/d are seldom required. Adjustment of the dose is based on serum alkaline phosphatase which is an important biomarker of the healing of rickets. Administration of oral phosphorus reduces ionised serum calcium, increasing serum PTH which if not reduced can cause secondary and in some cases, tertiary hyperparathyroidism [9]. Active vitamin D analogues are therefore required to suppress PTH rise and also increase 1,25 (OH)2D which is low because of high FGF23. Active vitamin D analogues can be either calcitriol at an initial dose of 20–30 ng/kg/d in 2 divided doses or alfacalcidol of 30–50 ng/kg/d once a day [8]. The excess dose of calcitriol/alfacalcidol can cause increased excretion of calcium in the urine which in combination with excess urinary phosphate excretion can cause nephrocalcinosis. In some children, calcimimetic Cinacalcet may be required to prevent the rise in PTH while allowing oral phosphorus to heal rickets [10]. The outcome of medical management is variable as standard treatment with phosphorus and active vitamin D analogues still do not address the primary problem of excess FGF23 which continues to remain high [11]. Burosumab is a recombinant human monoclonal antibody which inhibits the activity of FGF23 [12]. In phase 3 clinical trial, Burosumab, compared to standard treatment, reduced urinary excretion of phosphate, normalised serum phosphate concentration and improved patient-reported outcome measures [13]. Treatment over a period of time heals rickets and normalises serum alkaline phosphatase. It is given as subcutaneous injections once every 2 wk and has been licensed in many countries for the management of XLH [14]. Iron deficiency state can increase FGF23 concentration and therefore in FGF23-related hypophosphatemic rickets, it can significantly worsen hypophosphatemic rickets [15]. Iron deficiency state especially in menstruating children and adolescent females should be therefore, adequately addressed. There is evidence that early standard treatment reduces complications and improves height [16]. It is therefore crucial to make an early diagnosis by differentiating it from calcipenic rickets. Elevation of PTH differentiates between calcipenic and phosphopenic rickets and should be measured in initial screening blood tests for rickets.

Vitamin D is a biologically inactive prohormone, that exists either as cholecalciferol (vitamin D3) or ergocalciferol (vitamin D2). Cholecalciferol is synthesised by ultraviolet (UVB) radiation of 7-dehydroxycholesterol present in the skin, whereas ergocalciferol is synthesised by fungi and yeast. Activation of these forms of vitamin D requires hydroxylation at two sites. 25-hydroxylation by 25-hydroxylase (CYP2R1) occurs in the liver, with the product 25-hydroxyvitamin D (25OHD) being the most abundant form of circulating vitamin D metabolite and the best indicator of body stores of vitamin D [17]. 1α-hydroxylation of 25OHD by 1α-hydroxylase (CYP27B1) then occurs in the kidney to produce the active metabolite 1,25-dihydroxy vitamin D [1,25(OH)2D]. The expression and activity of this enzyme is positively and negatively regulated by parathyroid hormone and FGF-23 respectively. 1,25(OH)2D binds to the nuclear vitamin D receptor (VDR) to exert its effects. In relation to rickets, the main effects of vitamin D are on the gut to stimulate calcium and phosphate absorption. 24-hydroxylation of 25OHD and 1,25(OH)2D by 24-hydroxylase (CYP24A1) in the kidney to 24,25-dihydroxyvitamin D and 1,24,25-trihydroxyvitamin D respectively results in inactivation of these products. However, a separate inactivation pathway for 25OHD and 1,25(OH)2D has more recently been established, by CYP3A4 in the liver [18].

VDDR refers to a group of conditions characterised by abnormalities in the pathway of vitamin D metabolism resulting in the reduced action of vitamin D (primarily intestinal calcium and phosphate absorption), which causes hypocalcemia, rickets and secondary hyperparathyroidism. Five types are recognised. Types of VDDR1 refer to abnormalities in producing active vitamin D, types of VDDR2 refer to abnormalities in VDR function and VDDR3 results in excessive inactivation of vitamin D. Table 3 summarises the features of each form of VDDR.

This condition is due to biallelic mutations in CYP27B1 on chromosome 12q14.1. This results in an inability to 1α-hydroxylate 25OHD and subsequently an inability to produce active vitamin D. Some genotype-phenotype correlations are noted, depending on residual enzyme activity, although the majority of mutations result in complete loss of enzyme activity [19]. Children with this condition tend to present during infancy with hypocalcemic seizures, or in childhood with rickets, hypotonia and delayed motor development [20]. In the longer term, these children suffer from progressive skeletal deformities and short stature, if untreated. The typical biochemical findings are of hypocalcemia, hypophosphatemia, hyperphosphatasia, secondary hyperparathyroidism, and normal or elevated 25OHD with extremely low 1,25(OH)2D. However, an inappropriately normal 1,25(OH)2D has also been observed in genetically proven cases, which can cause diagnostic confusion [21]. Treatment is typically with therapeutic doses of active vitamin D [calcitriol; 1,25(OH)2D, twice daily] or active vitamin D analogues (alfacalcidol; 1α-hydroxyvitamin D once daily), which bypass the need for 1α-hydroxylation (Table 3). High concentrations of 25OHD can bind to the VDR directly, therefore high doses of cholecalciferol or ergocalciferol can be provided, but they carry a greater risk of hypercalcemia, hypercalciuria and nephrocalcinosis, which requires monitoring in the long-term regardless of treatment option used. Treatment quickly resolves the biochemical abnormalities and undermineralised skeleton. Improvements in stature take longer to occur, with more successful growth outcomes noted with earlier diagnosis and treatment [22]. Delayed diagnosis can occur not only with milder mutations but also because of misdiagnosis as nutritional rickets.

This condition is similar to VDDR1a in clinical presentation but is due to mutations in CYP2R1 (located at chromosome 11p15.2), which encodes for 25-hydroxylase [23]. Thus, the key biochemical difference between these two conditions is of very low 25OHD, which again can be confused with nutritional rickets. Interestingly, a gene dose effect is observed with this gene, whereby individuals with homozygous mutations have a more severe phenotype, undetectable 25OHD concentrations and almost no response to loading doses of vitamin D, whereas individuals carrying heterozygous mutations had a milder phenotype, only slightly reduced 25OHD concentrations and some response to loading doses of vitamin D [23]. Furthermore, the phenotype of these heterozygous individuals seems to improve with age [23]. Treatment is either with therapeutic doses of calcitriol (which bypasses 25-hydroxylation requirements) or with very high doses of cholecalciferol, along with calcium supplementation (Table 3). More recently, the development of calcifediol (25-hydroxycholecalciferol, once daily), has allowed a more rational treatment approach to this specific condition to be successfully undertaken [24].

VDDR2a is due to biallelic mutations in VDR, the gene that encodes for the vitamin D receptor (VDR), located on chromosome 12q13.11. This results in resistance to 1,25(OH)2D. The vitamin D receptor is a nuclear receptor with an amino-terminal DNA-binding domain and a carboxy-terminal ligand-binding domain. When 1,25(OH)2D binds to the VDR, it heterodimerises with the retinoid-X receptor (RXR) before binding to vitamin D response elements (VDREs) in the promoter regions of vitamin D-regulated genes to initiate the transcription [25]. The clinical features and presentation of VDDR2a are similar to forms of VDDR1, except for the presence of partial or complete alopecia that develops within the first year of life. This alopecia is due to the role VDR plays in hair follicle cycling [26]. There appears to be a genotype-phenotype correlation in VDDR2a, whereby mutations affecting the ligand-binding domain tend to be present with a milder phenotype without alopecia, whereas mutations affecting the DNA-binding domain tend to be more severe, with poor response to therapy and the presence of alopecia [25]. Accordingly, alopecia can be used as a prognostic tool to predict severity, with the presence of alopecia associated with earlier diagnosis and greater treatment resistance [27]. The biochemistry of VDDR2a is similar to VDDR1a, except for elevated 1,25(OH)2D. Due to the resistance to 1,25(OH)2D, extremely high doses of active vitamin D or its analogues (preferably calcitriol) are required long-term, in addition to high doses of calcium supplementation (Table 3). In many cases, intravenous calcium supplementation through central venous access is required to achieve control of rickets and biochemical parameters. The response to treatment will be dependent upon residual VDR activity. Treatment will normalise biochemical parameters and will improve rickets with time, but the alopecia, if present, will persist. Interestingly, some cases have demonstrated an improvement with age, particularly following puberty, such that treatment requirements lessen [28]. This is thought to be due to the development of vitamin D-independent intestinal calcium absorption mechanisms with age [29].

This condition has the same biochemical and clinical features as VDDR2a, except without a mutation in the VDR gene [30]. Therefore, the two conditions cannot be separated clinically, only by genetic testing. A specific genetic mutation has not yet been identified for VDDR2b. The function of VDR and the VDR-RXR heterodimer are retained, unlike VDDR2a, with the pathology thought to be due to the over-expression of heterogenous nuclear ribonucleoprotein C1/C2, which inhibits binding of the VDR-RXR heterodimer to VDREs [31, 32]. The treatment is identical to that for VDDR2a (Table 3).

This has only been recently described as a form of VDDR due to gain-of-function mutations in CYP3A4 (located on chromosome 7q22.1), encoding a cytochrome P450 enzyme, resulting in increased inactivation of vitamin D metabolites [33]. Both cases described were short, with biochemical and radiological features of rickets. Both cases had detectable serum concentrations of vitamin D3, but low 25OHD and 1,25(OH)2D. These transiently increased with high doses of vitamin D3 or calcitriol, in keeping with the rapid degradation of vitamin D metabolites [33]. Thus, these cases will require lifelong treatment with high doses of cholecalciferol/ergocalciferol or active vitamin D or its analogues (Table 3). Interestingly, CYP3A4 has also been shown in in vitro studies to be the enzyme induced by P450-inducing drugs (such as rifampicin, carbamazepine and phenobarbital) to result in drug-induced osteomalacia [34].

Although specific clinical, biochemical and treatment aspects have been referred to for each type of VDDR above, it is important to recognise some principles that are common to all forms. Calcium supplementation is often required, at the very least initially, in all forms of VDDR (Table 3). This is not only to address the presenting hypocalcemia but also to prevent further hypocalcemia that may occur due to the “hungry bones” during remineralisation upon commencing treatment. Secondary hyperparathyroidism is a universal feature of VDDR and will cause demineralisation of the bones. Adequate treatment of VDDR will hopefully resolve this in a timely manner, but the development of tertiary hyperparathyroidism needs to be monitored in cases of prolonged secondary hyperparathyroidism, with the use of cinacalcet considered in such cases [35]. Finally, regular biochemical monitoring is essential when treating all forms of VDDR. Under-treatment can be identified with ongoing hypocalcemia, hyperphosphatasia and secondary hyperparathyroidism, as well as with intermittent radiographs. As importantly, over-treatment must be avoided to prevent hypercalciuria and nephrocalcinosis with monitoring of urinary calcium-to-creatinine ratios undertaken to identify hypercalciuria.

Although nutritional calcium and vitamin D deficiency is the commonest cause of rickets, rarer ‘refractory’ causes of rickets affecting phosphate and vitamin D metabolism, must be considered based particularly on specific biochemical findings, but also radiographic and clinical features, so that appropriate treatment and monitoring can be initiated in a timely manner.